R&D | January 06, 2026
Insilico Medicine teams up with Servier to fast-track AI-driven cancer drugs
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
The first project will focus on developing an AI-based platform for the sterically guided design of bispecific antibodies
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
Thermo Fisher and Symphogen extend their collaboration using innovative and efficient workflows to improve data confidence, aiding the creation of new cancer treatments
Subscribe To Our Newsletter & Stay Updated
